ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ATRN-119’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ATRN-119 is under development for the treatment of advanced solid tumors including ovarian cancer, endometrial cancer, cervical cancer, colon cancer, breast cancer and prostate cancer. The drug candidate is administered through oral route. It acts by targeting ataxia telangiectasia and rad3-related (ATR). These are developed based on Atrize platform technology.
Aprea Therapeutics overview
Aprea Therapeutics is a biopharmaceutical company that develops cancer therapeutics that reactivate mutant tumor suppressor protein, p53. Its DDR products pipeline includes ATRN-119 and ATRN-W1051. The company also offers products such as APR-246 drugs and therapeutics for myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and additional hematologic and solid tumor malignancies. It also has pre-clinical research and development to extend its product development. The company operates offices in Sweden and the US. Aprea Therapeutics is headquartered in Doylestown, Pennsylvania, the US.
For a complete picture of ATRN-119’s drug-specific PTSR and LoA scores, buy the report here.